Can Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Continue To Move The Needle?

Wall Street sell-side analysts are projecting Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to grow at an accelerated rate over the next 5 years.  Brokerage firms are looking for the firm to grow 43.37% over the next year and 22.00% over the next five years.

EPS measures what each share is worth and also indicates how much money their sharehoders would gain if the company was to pay out all of its profits.  Supernus Pharmaceuticals, Inc.’s trailing 12- months EPS is 1.10.  Last year, their EPS growth was 525.60% and their EPS growth over the past five years was 29.10%.  


Let’s start off by taking a look at how the stock has been performing recently.  Over the past twelve months, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock was 49.70%.  Last week, it was -8.03%, -14.67% over the last quarter, and  12.67% for the past half-year. 

Over the past 50 days, Supernus Pharmaceuticals, Inc. stock was -24.47% off of the high and 13.51% removed from the low.  Their 52-Week High and Low are noted here.  -24.47% (High), 83.94%, (Low). 


Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s performance this year to date is 49.70%.  The stock has performed -8.03% over the last seven days, -8.59% over the last thirty, and -14.67% over the last three months.  Over the last six months, Supernus Pharmaceuticals, Inc.’s stock has been 12.67% and 75.00% for the year.


Wall Street analysts are have a consensus analyst recommendation of 2.00 on the stock.  This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Brokerages covering the name have a $50.13 on the stock.

The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Leave a Comment